MedMira (FRA:47M) Cyclically Adjusted PB Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is MedMira Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


MedMira  (FRA:47M) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MedMira Cyclically Adjusted PB Ratio Related Terms


MedMira Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for MedMira's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedMira Cyclically Adjusted PB Ratio Chart

MedMira Annual Data
Trend Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MedMira Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:47M vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, MedMira's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MedMira's Cyclically Adjusted PB Ratio falls into.



MedMira Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MedMira's Cyclically Adjusted Book per Share for the quarter that ended in Apr. 2026 is calculated as:

For example, MedMira's adjusted Book Value per Share data for the three months ended in Apr. 2026 was:

Adj_Book=Book Value per Share/CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=-0.022/132.7364*132.7364
=-0.022

Current CPI (Apr. 2026) = 132.7364.

MedMira Quarterly Data

Book Value per Share CPI Adj_Book
201607 -0.008 101.844 -0.010
201610 -0.008 102.002 -0.010
201701 -0.008 102.318 -0.010
201704 -0.009 103.029 -0.012
201707 -0.010 103.029 -0.013
201710 -0.010 103.424 -0.013
201801 -0.010 104.056 -0.013
201804 -0.011 105.320 -0.014
201807 -0.011 106.110 -0.014
201810 -0.012 105.952 -0.015
201901 -0.013 105.557 -0.016
201904 -0.013 107.453 -0.016
201907 -0.014 108.243 -0.017
201910 -0.015 107.927 -0.018
202001 -0.015 108.085 -0.018
202004 -0.015 107.216 -0.019
202007 -0.015 108.401 -0.018
202010 -0.014 108.638 -0.017
202101 -0.015 109.192 -0.018
202104 -0.016 110.851 -0.019
202107 -0.016 112.431 -0.019
202110 -0.017 113.695 -0.020
202201 -0.012 114.801 -0.014
202204 -0.013 118.357 -0.015
202207 -0.013 120.964 -0.014
202210 -0.014 121.517 -0.015
202301 -0.013 121.596 -0.014
202304 -0.014 123.571 -0.015
202307 -0.015 124.914 -0.016
202310 -0.016 125.310 -0.017
202401 -0.016 125.072 -0.017
202404 -0.016 126.890 -0.017
202407 -0.017 128.075 -0.018
202410 -0.018 127.838 -0.019
202501 -0.020 127.443 -0.021
202504 -0.020 129.102 -0.021
202507 -0.020 130.290 -0.020
202510 -0.020 130.603 -0.020
202601 -0.021 130.366 -0.021
202604 -0.022 132.736 -0.022

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MedMira Business Description

Other Exchanges MMIRF:USAMIR:Canada
Address 155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company engaged in the research, development, and manufacturing of rapid diagnostics and technologies. The company operates in one reportable operating segment, rapid diagnostic products and services. Its product line includes HIV, COVID-19, syphilis, Multiplex, Miriad RVF Toolkit, and H. pylori. The company generates revenue from North America, Europe, and other regions, with the majority generated from North America.